Evidence map›Paper›PMID 39846514›Full record

ArticleBiotechnology progress

Harnessing cell aggregates for enhanced adeno-associated virus manufacturing: Cultivation strategies and scale-up considerations.

Brian Ladd, Torbjörn Gräslund, Véronique Chotteau

Abstract read
In one paragraph

Article in Biotechnology progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Brian LaddAdBIOPRO, VINNOVA Competence Centre for Advanced Bioproduction by Continuous Processing, Royal Institute of Technology (KTH), Stockholm, Sweden.ORCID 0009-0002-0379-016X
Torbjörn GräslundAdBIOPRO, VINNOVA Competence Centre for Advanced Bioproduction by Continuous Processing, Royal Institute of Technology (KTH), Stockholm, Sweden.
Véronique ChotteauAdBIOPRO, VINNOVA Competence Centre for Advanced Bioproduction by Continuous Processing, Royal Institute of Technology (KTH), Stockholm, Sweden.

Funding

Cobra Biologics, Science Park University of Keele, Keele, Newcastle ST5 5SP, United KingdomCytiva, Björkgatan 30, 753 23 UppsalaHorizon 2020 Framework Programme 813453VINNOVA 2016-05181
6 · The paper itself

Abstract

The possibility to produce recombinant adeno-associated virus (rAAV) by adherent HEK293T cells was studied in a stirred tank bioreactor (STR) culture of cell aggregates. A proof-of-concept of rAAV production was successfully demonstrated in a process where single cells were first expanded, then cell aggregates were formed by dilution into a different medium 1 day before triple plasmid transfection was conducted. An alternative approach for the STR inoculation using a seed taken from a high cell density perfusion (HCDP) culture was also investigated. It was, however, found that the spent medium of the HCDP inhibited the transfection of HEK293T cell aggregates, which was confirmed when testing with single-cell suspension culture. The formation of aggregates in shaken multi-well plates was also investigated to develop a screening system using the average power input as a scale-down criterion, which revealed that cell aggregates could be generated in 12-well plates, however with a larger size than in a STR. Taking into account the reported higher rAAV production of adherent cells in comparison with single cells for triple-plasmid transfection, HEK293T cell aggregates can possibly surpass single-cell suspension in space-time rAAV yield. The formation of HEK293T cell aggregates in a STR system offers a promising approach for scaling up and intensifying rAAV production by triple-plasmid transfection, in comparison with traditional 2D scale-up methods.

Indexed as

Cell Culture TechniquesDependovirusVirus CultivationBioreactorsCell AggregationHEK293 CellsHumansTransfectionintensificationrAAVscale‐uptransfectionviral vectors

Identifiers

PMID39846514
PMCPMC12171334

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.